Inmune Bio Inc.
INMB· Nasdaq
Released Aug 4, 2021, after the close
10-Q filed Aug 4, 2021, 35 days after period end · 0001213900-21-040314
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | $0.00 | — | $0.00 | $0.00 |
| Net Income | -$6.66M | -$2.11M | -$392.08K | -$6.17M |
| EPS Diluted | -$0.44 | -$0.20 | -$0.04 | -$0.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inmune Bio Inc. · CIK 1711754 · Engraved from SEC EDGAR